A viral assembly inhibitor blocks SARS-CoV-2 replication in airway epithelial cells

Li Du,Fred Deiter,Mohamed S. Bouzidi,Jean-Noël Billaud,Graham Simmons,Prerna Dabral,Suganya Selvarajah,Anuradha F. Lingappa,Maya Michon,Shao Feng Yu,Kumar Paulvannan,Balaji Manicassamy,Vishwanath R. Lingappa,Homer Boushey,John R. Greenland,Satish K. Pillai
DOI: https://doi.org/10.1038/s42003-024-06130-8
IF: 6.548
2024-04-23
Communications Biology
Abstract:The ongoing evolution of SARS-CoV-2 to evade vaccines and therapeutics underlines the need for innovative therapies with high genetic barriers to resistance. Therefore, there is pronounced interest in identifying new pharmacological targets in the SARS-CoV-2 viral life cycle. The small molecule PAV-104, identified through a cell-free protein synthesis and assembly screen, was recently shown to target host protein assembly machinery in a manner specific to viral assembly. In this study, we investigate the capacity of PAV-104 to inhibit SARS-CoV-2 replication in human airway epithelial cells (AECs). We show that PAV-104 inhibits >99% of infection with diverse SARS-CoV-2 variants in immortalized AECs, and in primary human AECs cultured at the air-liquid interface (ALI) to represent the lung microenvironment in vivo. Our data demonstrate that PAV-104 inhibits SARS-CoV-2 production without affecting viral entry, mRNA transcription, or protein synthesis. PAV-104 interacts with SARS-CoV-2 nucleocapsid (N) and interferes with its oligomerization, blocking particle assembly. Transcriptomic analysis reveals that PAV-104 reverses SARS-CoV-2 induction of the type-I interferon response and the maturation of nucleoprotein signaling pathway known to support coronavirus replication. Our findings suggest that PAV-104 is a promising therapeutic candidate for COVID-19 with a mechanism of action that is distinct from existing clinical management approaches.
biology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to develop a new anti - SARS - CoV - 2 drug to overcome the problem of decreased efficacy of existing treatment regimens (such as vaccines and monoclonal antibodies) against viral variants. Specifically, the research focuses on discovering the small - molecule drug PAV - 104 that can inhibit the replication of SARS - CoV - 2 in human respiratory epithelial cells and exploring its mechanism of action. The paper points out that although there are currently multiple vaccines available, the proportion of fully vaccinated people worldwide is only 65.4%, and due to insufficient access to vaccines, resistance to vaccination in some populations, and the increased risk of severe COVID - 19 in immunocompromised individuals, it is particularly important to find effective antiviral drugs. In addition, existing antiviral drugs such as Remdesivir, Molnupiravir, and Paxlovid are effective to some extent, but also have problems such as side effects or poor efficacy. Therefore, through screening small molecules in the extracellular protein synthesis and assembly system, this study discovered the compound PAV - 104. The experimental results show that PAV - 104 can significantly inhibit the infection rate of SARS - CoV - 2 in different variants by more than 99%, and its mechanism of action is different from existing drugs. It mainly interferes with the oligomerization of the viral nucleocapsid protein (N protein), prevents the assembly of virus particles, and thus inhibits virus replication. At the same time, PAV - 104 can also reverse the SARS - CoV - 2 - induced type I interferon response and the maturation of the nucleoprotein signaling pathway, showing great potential as a potential treatment candidate for COVID - 19.